Exciting news was shared in the January 2015 issue of Mycoses, with clinical data revealing that the use of Caspofungin to treat invasive fungal disease in leukemia patients was both positive and responsive. Adult patients who were diagnosed with acute lymphoblastic leukemia attained relief from their suspected fungal disease after the clinical use of Caspofungin.[…]
Caspofungin Therapy Aids ALL Patients with Invasive Fungal Disease
Anti-Fungal, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: acute lymphoblastic leukemia Jun 12, 2015
Clofarabine to Be a Life Saver for Relapsed or Refractory Acute Lymphoblastic Leukemia
Chemotherapeutic / Anti-Neoplastic, Patent Expiration 2018 Tags: acute lymphoblastic leukemialeukemia Aug 27, 2013
Clofarabine, CAS# 123318-82-1, is also known as the brand name Clolar. As an injectable medication used to treat relapsed or refractory acute lymphoblastic leukemia, clofarabine is typically administered after at least two prior regimens. Clofarabine is indicated for the pediatric population, ages 1 to 21 years of age. A common treatment regimen is 52 mg/m2[…]
Prepare for the Future Exaction of Oncology Products
Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: 159351-69-6191732-72-6acute lymphoblastic leukemiaBortezomibEverolimusLenalidomideleukemiamultiple myeloma Jul 05, 2012
The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007. Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]
The Need for Anthracyclines Grows
Anthracycline, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, TEVA API Tags: acute lymphoblastic leukemiaAnthracyclinesmetastatic breast cancer Jun 06, 2012
The latest headline is daunting, with the World Health Organization’s International Agency for Research on Cancer announcing a 75 percent increase in cancer cases worldwide by 2030. This astounding prediction, published in Reuters on June 1, 2012 offered an unfortunate reality, based on data from GLOBOCAN. Causes are thought to be poor lifestyle choices worldwide,[…]
New Drugs and Therapies at the Forefront of Treatment for Acute Lymphoblastic Leukemia
Chemotherapeutic / Anti-Neoplastic, LGM Pharma, Press Release Tags: acute lymphoblastic leukemiaMendy SchurderRobert Hoppes Apr 17, 2012
Local firm supplies active pharmaceutical ingredients to various global pharmaceutical companies who develop new therapies. BOCA RATON, Florida – Promising news for families with children suffering from acute lymphoblastic leukemia, or ALL, was recently published in Reuters Health. Results were released from a study conducted at the University of Colorado School of Medicine and Children’s[…]
New Drugs and Therapies at the Forefront of treatment for Acute Lymphoblastic Leukemia
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic, FDA Approval News, Immunosuppressant Tags: acute lymphoblastic leukemiaHerceptinimatinibleukemiaMethotrexateTrastuzumab Mar 30, 2012
J.R.Stokes Illustrations: Natural Killer: T-cell vs. Leukemia Researchers received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. The group of oncology advisers voted 7-4 endorsing the Vincristine Sulfate CAS# 2068-78-2 liposomal injection, also known as the brand[…]
